Mutations inhibiting KDM4B drive ALT activation in ATRX-mutated glioblastomas
Alternative Lengthening of Telomeres (ALT) is a telomere maintenance pathway utilised in 15% of cancers that have been associated with mutations in ATRX. Here the authors reveal a functional role of histone demethylases KDM4B in regulating ALT activation.
Guardado en:
Autores principales: | M. Udugama, L. Hii, A. Garvie, M. Cervini, B. Vinod, F.-L. Chan, P. P. Das, J. R. Mann, P. Collas, H. P. J. Voon, L. H. Wong |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b39a9f1db7b5499c894032806f9966a3 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Inhibition of a K9/K36 demethylase by an H3.3 point mutation found in paediatric glioblastoma
por: Hsiao P. J. Voon, et al.
Publicado: (2018) -
MYCN amplification and ATRX mutations are incompatible in neuroblastoma
por: Maged Zeineldin, et al.
Publicado: (2020) -
Alternative lengthening of telomeres is not synonymous with mutations in ATRX/DAXX
por: Alexandre de Nonneville, et al.
Publicado: (2021) -
Formal reply to “Alternative lengthening of telomeres is not synonymous with mutations in ATRX/DAXX”
por: Lars Feuerbach
Publicado: (2021) -
Absence of AKT1 mutations in glioblastoma.
por: Fonnet E Bleeker, et al.
Publicado: (2009)